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The use of theCD38monoclonal antibody daratumumab in combinationwith standard
myeloma chemotherapy regimens has been studied extensively in recent years. We
undertook an updated meta-analysis of phase III randomized controlled trials (RCT)
to determine the efficacy of daratumumab combination regimens. The relative risk for
progressionwas significantly lower in daratumumab-treated cohorts (HR 0.46, 95%CI
0.38-0.55) and this was consistent across newly diagnosed and relapsed cases. No sta-
tistically significant improvementwas identified in newly diagnosedpatientswith high-
risk cytogenetics and this group remains a therapeutic challenge.
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1 INTRODUCTION
Multiple myeloma (MM) is a hematological malignancy characterized
by monoclonal proliferation of abnormal plasma cells, which accounts
for one percent of all cancersworldwide [1].MMremains incurable and
complicated by end-organ damage, including anemia, hypercalcemia,
renal dysfunction, and lytic lesions in the bone [2]. MM ultimately pro-
gresses or relapses and remains a therapeutic challenge [3]. Over the
past two decades, proteasome inhibitors (PI) and immunomodulatory
drugs (IMiDs) have improved survival in patients with MM [4]. Intro-
ducing novel agents has recently become the hallmark of a therapeutic
paradigm shift in the management of newly diagnosed MM (NDMM)
and relapsed or refractory MM (RRMM), in both transplant – eligible
and – ineligible patients [5]. Daratumumab is a human immunoglobulin
G1 kappa (IgG1κ) monoclonal antibody that can bind to CD38 on
the surface of myeloma cells and lead to cell lysis [6]. Studies have
shown that daratumumab monotherapy or in combination with PIs,
IMiDs, and/ or other anti-myeloma therapies increased survival in the
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treatment ofMM.We undertook an updatedmeta-analysis of phase III
randomized controlled trials (RCT) to determine the efficacy of dara-
tumumab combination regimens in patients with NDMMand RRMM.
2 METHODS
The systematic review was performed as per the Cochrane Handbook
for Systematic Reviews and reported in accordancewith the Preferred
Reporting Items for Systematic Reviews andMeta-Analyses (PRISMA)
guidelines [7]. We performed systematically a comprehensive litera-
ture searchusingMEDLINE, EMBASEdatabases andmeeting abstracts
up to30th April 2020using thekeywords “multiplemyelomaANDdara-
tumumab,” OR “plasma cell disorder AND daratumumab.” The refer-
ences of all potential studies were also reviewed for any additional
relevant studies. We limited the search to “humans” and “randomised
controlled trials.” All studies written in English or non-English lan-
guages were obtained. The studies that were eligible to be included
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TABLE 1 Characteristics of the studies included in themeta-analysis
Number of Patients
Study Author/Year Study Type
Study





III Untreated patients who
are ineligible for stem
cell transplantation
350 356 DVMP VMP

















543 542 DVTDex VTDex
POLLUX Bahlis/2020 Randomised, open-label,
multicentre
III Relapsed or refractory
multiple myeloma
281 276 DRDex RDex
CASTOR Spencer/2018 Multicentre, randomised,
open-label,
active-controlled
III Relapsed or relapsed and
refractorymultiple
myeloma
240 234 DVDex VDex
CANDOR Usmani/2019 Randomised, open label, III Relapsed or relapsed and
refractorymultiple
myeloma
312 154 KDDex KDex
Abbreviations: D, daratumumab; V, bortezomib;M, melphalan; P, prednisolone; R, lenalidomide; Dex, dexamethasone; T, thalidomide; K, carfilzomib.
in the meta-analysis had to conform with the following character-
istics: phase III RCTs utilizing daratumumab in patients with newly
diagnosed/untreated multiple myeloma or relapsed/refractory multi-
ple myeloma.
The primary outcome of our meta-analysis was progression-free
survival (PFS). The secondary outcome was the overall response
rate (ORR), including stringent complete response (sCR), complete
response (CR), and MRD negativity (molecular response). We sum-
marized the characteristic features of incorporated studies in Table 1
[8–13]. Six phase III RCTs (POLLUX, CASTOR, CANDOR, ALCYONE,
CASSIOPEIA, andMAIA studies) involving 4025 patients (2094 partic-
ipants in daratumumab group and 1931 cases in control group) were
included in the final analysis. Studies compared daratumumab based
combination regimens with antimyeloma regimens without daratu-
mumab as shown inTable 1. Daratumumabwas utilized in relapsed and
refractory multiple myeloma in the POLLUX, CASTOR, and CANDOR
studies, and as first-line treatment for patients with multiple myeloma
in the ALCYONE, CASSIOPEIA, and MAIA studies. The randomization
ratio was 1:1 in all studies except 2:1 in the CANDOR trial. Mantel-
Haenszel (MH) method was used to estimate the pooled hazard ratio
(HR) for progression-free survival (PFS), and pooled risk ratio (RR), and
risk difference (RD) with 95% confidence interval (CI) for ORR, CR,
and sCR and MRD. All statistical analyses were performed using the
Review Manager, version 5.3 (Nordic Cochrane Centre; Copenhagen,
Denmark). Heterogeneity was assessedwith I2 and Cochran’s Q statis-
tic [14]. A “P-value” of <.05 was considered significant and I2 > 50% is
considered substantially heterogeneous. An HR < 1.0 or RR < 1.0 was
in favor of daratumumab. The risk of bias for each study was evaluated
by Cochrane RevMan 5.3 software. Five main salient biases (selection
bias, performancebias, detectionbias, attritionbias, reportingbias, and
others) were categorized and were rated as low, high, or unclear risk
[14]. Publication bias was assessed by funnel plots.
3 RESULTS
The I2 statistic showed some heterogeneity among RCTs and the
random-effects model was applied to provide a more conservative
result. The pooled HR for overall PFS was statistically significant at .46
(95% CI: 0.38–0.55; P < .00001) Figure 1A. The pooled HR for PFS
was calculated for each subset; NDMM in Figure 1B (HR, 0.54; 95%
CI: 0.46–0.63; P < .00001) and RRMM in Figure 1C (HR, 0.44; 95%
CI: 0.30–0.64; P < .0001). Although the pooled HR for PFS was sig-
nificant in standard-risk cytogenetic NDMM cohort in Figure 1D (HR,
0.43; 95% CI: 0.35–0.53; P < .00001), PFS was not statistically signifi-
cant in high risk cytogeneticNDMMcohort in Figure 1E (HR, 0.76; 95%
CI: 0.53–1.10; P = .15). A PFS benefit was observed in both standard-
risk cytogenetic and high-risk cytogenetic cohorts in RRMM with the
pooled HR of 0.38 (95% CI: 0.25–0.58; P < .00001) and the HR of 0.46
(95% CI: 0.31–0.67; P < .0001), respectively in Figure 1F,G. According
to an analysis of two trials, which enrolled transplant-ineligibleNDMM
patients (ALCYONE and MAIA trials), the pooled HR for PFS was not
significant at 0.81 (95%CI: 0.52–1.26; P= .35) in patients with NDMM
who harbored high-risk cytogenetics.
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The benefit in ORR was observed in both NDMM and RRMM who
have received a daratumumab-containing regimen. In NDMM, ORR
was reported in 92.2% in daratumumab arm versus 82.8% in the
control arm (RR, 1.13; 95% CI: 1.01–1.26; P = .03). In RRMM, ORR
was 87% versus 71.3% in the control arm (RR, 1.22; 95% CI: 1.12–
1.32; P < .00001). In NDMM, the rate of CR and sCR was 17.9%
higher in daratumumab combination regimens compared to the con-
trol group (RR, 1.71; 95% CI: 1.47–1.99; P < .00001), whereas the
rate of CR and sCR was 22.5% higher in daratumumab arm in the
RRMM subgroup (RR, 2.57; 95% CI: 2.12–3.12; P < .00001). Higher
MRD 10−5 negativity was also observed in both NDMM and RRMM.
In NDMM, molecular remission was reported in 38.8% in the dara-
tumumab arm versus 22% in the control arm (RR, 2.49; 95% CI:
1.23-5.04; P = .01). In RRMM, molecular remission was reported in
18.4% of patients in the daratumumab arm versus 3.4% in the con-
trol arm and the pooled RR was significant at 5.73 (95% CI: 3.75–8.78;
P< .00001).
4 DISCUSSION
Daratumumab is an anti-CD38 monoclonal antibody that lyses abnor-
mal plasma cells through direct cytotoxicity to the cell and comple-
ment activation [6] as well as an immunomodulatory effect [15]. The
antitumor effect of daratumumab can be enhanced by the addition
of immunomodulatory drugs such as lenalidomide [6]. Recently, there
have been several studies comparing the efficacy and safety of dara-
tumumab combination regimens with non-daratumumab based anti-
myeloma therapies.
Our meta-analysis showed that daratumumab combination regi-
mens yielded better PFS than control arms in bothNDMMandRRMM.
The improvement in PFS was noted across all subgroups except in
NDMMwith high-risk cytogenetics. Further analysis revealed that the
PFS benefit was not observed in high-risk cytogenetic NDMMpatients
regardless of transplant eligibility. Only about 15% of the patients in
all three trials were in the high-risk cytogenetic group, so it remains
possible that the HR favoring daratumumab may become statistically
significant with greater numbers. There remains a significant need
for more novel approaches and therapeutics to address this high-risk
subset.
A higher molecular remission rate of 64% (MRD10−5) was reported
in the daratumumab group in NDMM in the CASSIOPEIA study
compared to 16% in patients with NDMMwho received daratumumab
combination regimens in the ALCYONE study and 24.1% in the MAIA
study. The ALCYONE and MAIA trials enrolled transplant-ineligible
patients and are relatively older populations with the mean age of
∼70 years whereas the CASSIOPEIA study included relatively younger
patients with amean age of 59 years and they were eligible to undergo
autologous stem cell transplantation. The differences in patient selec-
tion criteria may explain the differences in the rate of response and
impact on survival.
Despite the consistency of our findings, some caution should be
used in their interpretation. First, the studies used different standard
combination regimens, trial design, andmethodology,whichmight con-
found the analysis. Second, the overall survival data are still imma-
ture for a few trials and we used the abstract data for the CANDOR
trial. Individual patient data pooled meta-analysis would provide more
detailed and accurate analyses and confirm our findings. Lastly, trans-
lating clinical trial data into the real-world setting is of paramount
importance.
5 CONCLUSION
Our meta-analysis showed that daratumumab combination regimens
significantly improved PFS, ORR, CR, and sCR, and MRD negativity
compared to control arms in patients with NDMM and RRMM. The
improvement in PFS was noted across all subgroups except in NDMM
with high-risk cytogenetics. More randomized studies are necessary in
the future to explore further novel therapies and the optimal combi-
nation of anti-myeloma therapies to improve survival in patients with
NDMMwithin the high-risk cytogenetic subset.
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